

CRF-RII (N-20): sc-1826

BACKGROUND

Individuals suffering from Alzheimer's disease (AD) exhibit dramatic reductions in the content of corticotropin-releasing factor (CRF), increased expression of CRF receptors (CRFRs) and abnormalities in neuronal morphology in affected brain areas. In addition, AD patients show decreased concentrations of CRF in their cerebrospinal fluid, which may contribute to their cognitive impairment. A high affinity CRF binding protein, designated CRF-BP, has been discovered in postmortem brain samples from AD patients. CRF-BP serves to bind and inactivate CRF, reducing the pool of "free CRF" available to bind CRFRs. Two CRF receptors, designated CRF-RI and CRF-RII, exhibit distinct brain localizations. Two forms of CRF-RII, designated CRF-RII α and CRF-RII β , result from alternative mRNA splicing. Urocortin, an additional member of the CRF family, shares 63% sequence identity with urotensin and 45% sequence identity with CRF. Urocortin specifically binds to and activates CRF-RI and CRF-RII, but binds to CRF-RII more efficiently than CRF, suggesting that it may be the true, high affinity ligand for the CRF receptor type II.

CHROMOSOMAL LOCATION

Genetic locus: CRHR2 (human) mapping to 7p14.3; Crhr2 (mouse) mapping to 6 B3.

SOURCE

CRF-RII (N-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of CRF-RII of mouse origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-1826 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CRF-RII (N-20) is recommended for detection of CRF-RII of mouse, rat and, to a lesser extent, human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CRF-RII siRNA (h): sc-39916, CRF-RII siRNA (m): sc-39917, CRF-RII shRNA Plasmid (h): sc-39916-SH, CRF-RII shRNA Plasmid (m): sc-39917-SH, CRF-RII shRNA (h) Lentiviral Particles: sc-39916-V and CRF-RII shRNA (m) Lentiviral Particles: sc-39917-V.

Molecular Weight of CRF-RII: 53-66 kDa.

Positive Controls: BC3H1 cell lysate: sc-2299.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SELECT PRODUCT CITATIONS

- Hinkle, R.T., et al. 2003. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. *Am. J. Physiol. Endo. Metab.* 285: 889-898.
- Jirecek, S., et al. 2003. Detection of corticotropin-releasing hormone receptors R1 and R2 (CRH-R1, CRH-R2) using fluorescence immunohistochemistry in the myometrium of women delivering preterm or at term. *Wien. Klin. Wochenschr.* 115: 724-727.
- Liu, S., et al. 2005. Expression of type 1 corticotropin-releasing factor receptor in the guinea pig enteric nervous system. *J. Comp. Neurol.* 481: 284-298.
- Bamberger, A.M., et al. 2006. Corticotropin-releasing hormone modulates human trophoblast invasion through carcinoembryonic antigen-related cell adhesion molecule-1 regulation. *Am. J. Pathol.* 168: 141-150.
- Klimaviciute, A., et al. 2006. Corticotropin-releasing hormone, its binding protein and receptors in human cervical tissue at preterm and term labor in comparison to non-pregnant state. *Reprod. Biol. Endocrinol.* 4: 29.
- Gounko, N.V., et al. 2006. The dynamic developmental localization of the full-length corticotropin-releasing factor receptor type 2 in rat cerebellum. *Eur. J. Neurosci.* 23: 3217-3224.
- Tian, J.B., et al. 2006. Presynaptic localization of a truncated isoform of the type 2 corticotropin releasing factor receptor in the cerebellum. *Neuroscience* 138: 691-702.
- Krause, K., et al. 2007. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. *Horm. Metab. Res.* 39: 166-170.
- Jin, T.E. 2008. Involvement of corticotropin-releasing factor receptor 2 β in differentiation of dopaminergic MN9D cells. *Mol. Cells* 26: 243-249.
- Pringle, R.B., et al. 2008. Amphetamine treatment increases corticotropin-releasing factor receptors in the dorsal raphe nucleus. *Neurosci. Res.* 62: 62-65.
- Miceli, F., et al. 2009. Expression and subcellular localization of CRH and its receptors in human endometrial cancer. *Mol. Cell. Endocrinol.* 305: 6-11.
- Lukkes, J.L., et al. 2009. Early life social isolation alters corticotropin-releasing factor responses in adult rats. *Neuroscience* 158: 845-855.
- Kubo, Y., et al. 2010. Urocortin prevents indomethacin-induced small intestinal lesions in rats through activation of CRF2 receptors. *Dig. Dis. Sci.* 55: 1570-1580.
- Squillaciotti, C., et al. 2011. Expression of urocortin and corticotropin-releasing hormone receptors in the bovine adrenal gland. *Gen. Comp. Endocrinol.* 172: 416-422.
- Lukkes, J.L., et al. 2011. Topographical distribution of corticotropin-releasing factor type 2 receptor-like immunoreactivity in the rat dorsal raphe nucleus: co-localization with tryptophan hydroxylase. *Neuroscience* 183: 47-63.